Background: Curcuminoids are promising cancer chemopreventive agents. Curcumin, demethoxycurcumin (DMC) and bisdemethoxycurcumin (BDMC) are the major bioactive curcuminoids in turmeric. However, comprehensive metabolic studies of these three curcuminoids are still limited. Objective: To identify the metabolites of curcumin, DMC and BDMC in rats after oral administration of solid lipid nanoparticles (SLNs). Methods: Male Sprague-Dawley rats (250 ± 20 g, body weight) were randomly divided into 4 groups (n=3), and were orally administered with curcumin-SLN, DMC-SLN, BDMC-SLN, or blank-SLN, respectively. Plasma samples (500 μL) via the angular vein were collected at 1, 2 and 4 h post dosing, and the urine and feces samples were collected at 0-12 h and 12-24 h post-intake. An HPLC-DAD-ESI-MS n method was
INTRODUCTION
Curcumin, demethoxycurcumin (DMC) and bisdemethoxycurcumin (BDMC) are the major bioactive compounds of turmeric, which is derived from the rhizomes of Curcuma longa. For a long time, turmeric has been extensively used as a coloring and flavoring agent in different countries. In recent years, these curcuminoids have been considered as novel natural agents for the treatment and prevention of cancer. They possess a variety of significant biological activities, including antioxidant [1] [2] , anti-diabetes [3] , antimicrobial, anti-Alzheimer's disease [4] [5] , anti-inflammatory, and anti-tumorigenesis activities [6] [7] .
A number of studies have tried to reveal the in vivo metabolism of curcuminoids [8] [9] [10] . Detection of the parent compounds and their metabolites has been challenging due to poor bioavailability. Nanoparticle formulations have been reported to enhance water solubility and bioavailability of curcumin [11] [12] [13] . Recently, our group studied the pharmacokinetics of curcuminoids in mice tumor after oral administration of solid lipid nanoparticles (SLNs) [14] . The curcuminoids could be detected in tumor tissues at relatively high concentrations (C max between 24-285 ng/mL). However, the metabolism of curcuminoids after oral administration of SLNs has not been comprehensively studied.
In this work, we identified the metabolites of curcumin, DMC, and BDMC in rats plasma, urine and feces samples after oral administration of their SLNs by a sensitive highperformance liquid chromatography coupled with diode array detection and electrospray ionization tandem mass
Sample preparation
The plasma samples (300 μL) were mixed with 1200 μL acetonitrile by vortexing for 5 min, and then centrifuged at 9000 rpm for 10 min. The supernatant was transferred to a clean test tube and dried under a gentle flow of nitrogen gas at 35°C. The residue was reconstituted in 200 μL methanol. After filtering through a membrane (0.22-µm pore size), a 50-μL aliquot was injected for analysis.
The urine samples (2 ml) were mixed with ethyl acetate at the ratio of 1:4 (v/v) for three times. After vortexing for 5 min, the sample was centrifuged at 9000 rpm for 10 min, and the upper layer (ethyl acetate soluble fraction) was transferred to a clean test tube and dried under a gentle flow of nitrogen gas at 35°C. The residue was reconstituted in 200 μL methanol. After filtering through a membrane (0.22-µm pore size), a 50-μL aliquot was injected for analysis.
The feces samples (2 g) were extracted with 20 ml of methanol in an ultrasonic bath for 60 min, and then centrifuged at 9000 rpm for 5 min. After filtering through a membrane (0.22-µm pore size), a 50-μL aliquot was injected for analysis.
Enzyme hydrolysis
An aliquot of the treated plasma or urine sample (50 μL) was dried under nitrogen gas and mixed with 200 μL β-glucuronidase solution (containing 14.5 U/μL, in sodium acetate buffer, pH 5.5). The mixture was incubated at 37°C for 5 h, and then added with 800 μL methanol-acetonitrile (2:1), vortexed and centrifuged at 13,500 rpm for 10 min. The supernatant was dried under nitrogen gas stream and the residue was dissolved in 200 μL of methanol. After filtering through a membrane (0.22-µm pore size), a 50-μL aliquot was injected for analysis.
HPLC-DAD-ESI-MS n analysis
The analyses were performed using an Agilent Series 1100 HPLC instrument equipped with a diode-array detector (Agilent Technologies, Palo Alto, CA, USA). The samples were separated on a YMC Pack-ODS A C 18 column (4.6 mm × 250 mm, 5 µm) protected with an Agilent Zorbax SB-C 18 guard column (4.6 mm × 12.5 mm, 5 µm). The mobile phase consisted of acetonitrile (A) and 0.1% aqueous formic acid (B). The gradient elution program was as follows: 0 min, 5% A; 30 min, 45% A; 50 min, 95% A; 55 min, 95% A. The flow rate was 1 mL/min, and the column temperature was maintained at 30°C. A Finnigan LCQ Advantage ion trap mass spectrometer (Thermo Finnigan, San Jose, CA, USA) was connected to the Agilent 1100 HPLC system via an ESI source in a postcolumn splitting ratio of 3:1. Ultra-high purity helium (He) was used as the collision gas and high purity nitrogen (N 2 ) as the nebulizing gas. For negative ESI analysis, the optimized parameters were as follows: sheath gas (N 2 ), 50 arbitrary units; auxiliary gas (N 2 ), 10 units; ion spray voltage, 4.0 kV; capillary temperature, 330°C; capillary voltage, 35 V; tube lens offset voltage, −40 V; source-fragmentation voltage, 10 V; For full-scan MS analysis, the spectra were recorded in the range of m/z 120-1200. Data-dependent acquisition was used so that the two most abundant ions in each MS scan were selected in turn. The collision energy for CID was adjusted at 35% in analysis and the isolation width of precursor ions was 2.0 mass units.
RESULTS

Identification of metabolites from curcumin
A total of five phase II metabolites were identified from rat plasma after oral administration of curcumin-SLNs, No. [15] [16] [17] .
Identification of metabolites from DMC
As shown in Figure 1 Thus, M22 and M23 were tentatively identified as two isomers of hexahydrodemethoxycurcumin-O-sulfate. M22 showed MS/MS fragmentation transitions of m/z 423→ 259→179 and m/z 423→273→193. In contrast, M23 showed fragmentations of m/z 423→229→149 and m/z 423→ 243→163, indicating the sulfate group was located at the other side of the heptane chain. Moreover, the stronger signal of M23 indicated that it was more liable to form as a metabolite than M22, due to the steric hindrance of sulfate group and methoxy group. Simiarly, M17, M18 and M19 were identified as three isomers of octahydrodemethoxycurcumin-O-sulfate. M25 showed the MS/MS fragmentation transitions of m/z 419→339→233→218 and m/z 339→189, whereas M27 showed fragmentations of m/z 417→337→ 217→173 and m/z 337→187→143. These fragments were identical with previous reports [10, [18] [19] . Thus, M25 and M27
were identified as dihydrodemethoxycurcumin-O-sulfate and demethoxycurcumin-O-sulfate, respectively.
Identification of metabolites from BDMC
A total of five phase II metabolites were detected in rats plasma after oral administration of BDMC-SLNs, including m/z 309) was also detected in the urine sample, and was identified as the phase I metabolite dihydrobisdemethoxycurcumin.
